Panaccione, R <br/><br/>
Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease.  [electronic resource] 

 -  Alimentary pharmacology & therapeutics  Jun 2010 
 - 1296-309 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2036 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2036.2010.04304.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adalimumab<br/>Adult<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Crohn Disease--drug therapy<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Quality of Life<br/>Severity of Illness Index<br/>Time Factors<br/>Treatment Outcome